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Abstract: In this review, we take a survey of bioinformatics databases and quantitative structure-activity relationship studies 
reported in published literature. Databases from the most general to special cancer-related ones have been included. Most 
commonly used methods of structure-based analysis of molecules have been reviewed, along with some case studies where 
they have been used in cancer research. This article is expected to be of use for general bioinformatics researchers interested 
in cancer and will also provide an update to those who have been actively pursuing this ﬁ  eld of research.
Introduction
Bioinformatics has played a crucial role in structure based drug and target discovery, diagnosis and 
analysis of various diseases and their diversity. In particular there is enormous potential of its applica-
tion in cancer research, which has only been partially exploited so far. Essentially all bioinformatics 
starts with a database and proceeds to some kind of knowledge discovery and prediction. In this 
article, we review bioinformatics databases and different types of quantitative structure-activity rela-
tionship (QSAR) studies, which have either been used in cancer research or have the potential of such 
application.
Bioinformatics databases
Biological experiments result in useful information. This information has remained scattered in pub-
lished literature, technical lab reports and patent ﬁ  les until not very long ago. However, there has been 
a tremendous effort during last couple of decades to compile, share, standardize and model biological 
information (e.g. Wu et al. 2003; Bairoch and Boeckmann 1991; Benson et al. 2005; Hamosh et al. 
2005; Bateman et al. 2004; Boguski et al. 1993; Bauer et al. 2005; Smigielski et al. 2000; Wu et al. 
2001; Berman 2000; Hulo et al. 2006; Attwood et al. 2000; Gromiha et al. 1999; Mulder et al. 2002; 
Pongor et al. 1992; Kanehisa and Goto 2000; Dowell et al. 2001;). There has also been relatively recent 
interest in improving the quality of databases, developing web-interfaces and integration of databases 
(Achard et al. 2001; He et al. 2005; Hanisch et al. 2002; Westbrook et al. 2002; Arauzo-Bravo and 
Ahmad 2005). These efforts have made it possible to know the state of the art in a given area of biology 
and provide a basis for what is sometimes called in-silico biology, as opposed to in-vivo and in-vitro 
biology. Some of the most widely used databases have been listed in Table 1.
Table 1. General Bioinformatics Databases.
Major sequence repositories
DNA Data Bank of Japan (DDBJ) http://www.ddbj.nig.ac.jp All known nucleotide and protein 
sequences; International Nucleotide 
Sequence Database Collaboration
EMBL Nucleotide Sequence 
Database
http://www.ebi.ac.uk/embl.html All known nucleotide and protein 
sequences; International Nucleotide 
Sequence Database Collaboration
GenBank http://www.ncbi.nlm.nih.gov/ All known nucleotide and protein 
sequences; International Nucleotide 
Sequence Database Collaboration
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Table 1. General Bioinformatics Databases (Continued)
Major sequence repositories
NCBI Reference 
Sequence Project
http://www.ncbi.nlm.nih.gov/RefSeq/ Non-redundant collection of 
naturally-occurring biological 
molecules
Ensembl http://www.ensembl.org/ Annotated information on 
eukaryotic genomes
UCSC Genome Browser http://genome.ucsc.edu/ Genome assemblies and 
annotation
UniGene http://www.ncbi.nlm.nih.gov/UniGene/ Non-redundant, gene-oriented 
clusters
Protein Databases
CSDBase http://www.chemie.uni-marburg. 
de/∼csdbase/
Cold shock domain-containing 
proteins
DExH/D Family Database http://www.helicase.net/dexhd/ 
dbhome.htm
DEAD-box, DEAH-box and 
DExH-box proteins
Endogenous GPCR List http://www.tumor-gene.org/GPCR/ 
gpcr.html
G protein-coupled receptors; 
expression in cell lines
EXProt http://www.cmbi.Kun.nl/EXProt/ Proteins with experimentally-
veriﬁ  ed function
GenProtEC http://genprotec.mbl.edu E. coli K-12 genome, gene 
products and homologs
Histone Database http://research.nhgri.nih.gov/
histones/
Histone and histone fold 
sequences and structures
HIV Molecular http://hiv-web.lanl.gov/content/ HIV epitopes
Immunology Database immunology/index
HIV RT and Protease 
Sequence Database
http://hivdb.stanford.edu HIV reverse transcriptase and 
protease sequences
Homeodomain 
Resource genomic
http://genome.nhgri.nih.gov/ 
homeodomain/
Homeodomain sequences, 
structures and related genetic 
and genomic information
HUGE http://www.kazusa.or.jp/huge/ Large (>50 kDa) human 
proteins and cDNA sequences
IMGT http://imgt.cines.fr Immunoglobulin, T cell recep-
tor and MHC sequences from 
human and other vertebrates
IMGT/HLA http://www.ebi.ac.uk/imgt/hla/ Polymorphic sequences of 
human MHC and related genes
IMGT/MHC Database http://www.ebi.ac.uk/ipd/mhc/
index.html
Major histocompatibility 
complex sequences
InBase http://www.neb.com/neb/
inteins.html
All known inteins (protein 
splicing elements): properties, 
sequences, bibliography
InterPro http://www.ebi.ac.uk/interpro Protein families and domains
LGICdb http://www.ebi.ac.uk/compneur-srv/ 
LGICdb/LGICdb.php
Ligand-gated ion channel 
subunit sequences
Nuclear Protein Database 
(NPD)
http://npd.hgu.mrc.ac.uk Proteins localized in the 
nucleus
NRMD http://www.receptors.org/NR/ Nuclear receptor superfamily
NUREBASE http://www.ens-lyon.fr/LBMC/laudet/ 
nurebase.html
Nuclear hormone receptors
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Table 1. General Bioinformatics Databases (Continued)
Protein Databases
ooTFD http://www.ifti.org/ootfd Transcription factors and gene 
expression
PANTHER http://www.pantherdb.org/ Gene products organized by 
biological function
Peptaibol http://www.cryst.bbk.ac.uk/
peptaibol/ home.shtml
Peptaibol (antibiotic peptide) 
sequences
Phospho.ELM http://phospho.elm.eu.org/ Protein phosphorylation sites
PKR http://www.kinasenet.org/pkr/ 
Welcome.do
Protein kinase sequences, 
enzymology, genetics and molecular 
and structural properties
Prolysis http://delphi.phys.univ-tours.fr/
Prolysis/
Proteases and natural or synthetic 
protease inhibitors
Protein Information
Resource (PIR)
http://pir.georgetown.edu Comprehensive, annotated, 
non-redundant protein sequence 
databases
ProtoNet http://www.protonet.cs.huji.ac.il/ Hierarchical clustering of protein 
sequences
RTKdb http://pbil.univ-lyon1.fr/RTKdb/ Receptor tyrosine kinase sequences
SEVENS http://sevens.cbrc.jp 7-transmembrane helix receptors
SWISS-PROT/TrEMBL http://www.expasy.org/sprot Curated protein sequences
TIGRFAMs http://www.tigr.org/TIGRFAMs Functional identiﬁ  cation of proteins
trEST, trGEN, Hits http://hits.isb-sib.ch Hypothetical protein sequences
Structure
ASTRAL http://astral.stanford.edu/ Sequences of 
domains of known structure, 
selected subsets and sequence-
structure correspondences
BioMagResBank acids http://www.bmrb.wisc.edu/ NMR spectroscopic data from 
proteins, peptides, and nucleic acids
CATH http://www.biochem.ucl.ac.uk/bsm/ 
cath_new
Protein domain structures
CKAAPs DB http://ckaaps.sdsc.edu/perl/browser.
pl
Structurally-similar proteins with 
dissimilar sequences
CSD http://www.ccdc.cam.ac.uk/prod-
ucts/csd/
Crystal structure information for 
organic and metal organic 
compounds
Database of 
Macromolecular 
Movements
http://bioinfo.mbb.yale.edu/Mol-
MovDB/
Descriptions of protein and 
macromolecular motions, including 
movies
Decoys ‘R’ Us http://dd.stanford.edu/ Computer-generated protein confor-
mations based on sequence data
DSMM http://projects.eml.org/mcm/data-
base/ dsmm
Database of Simulated Molecular 
Motions
Gene3D http://cathwww.biochem.ucl.ac.
uk:8080/ Gene3D/
Precalculated structural assignments 
for genes within whole genomes
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Table 1. General Bioinformatics Databases (Continued)
Structure
GTOP http://spock.genes.nig.ac.jp/∼genome/ 
gtop.html
Protein fold predictions from genome 
sequences
HIC-Up http://alpha2.bmc.uu.se/hicup/ Structures of small molecules 
(‘hetero-compounds’)
HSSP http://www.sander.ebi.ac.uk/hssp/ Structural families and alignments; 
structurally-conserved regions and 
domain architecture
LPFC http://smi-web.stanford.edu/projects/ 
helix/LPFC/
Library of protein family core 
structures
MMDB linked http://www.ncbi.nlm.nih.gov/Structure/ All experimentally-determined three-
dimensional structures, linked to 
NCBI Entrez
ModBase http://modbase.compbio.ucsf.edu/ 
modbase-cgi-new/index.cgi
Annotated comparative protein 
structure models
NDB http://ndbserver.rutgers.edu/ Nucleic acid-containing structures
NTDB http://ntdb.chem.cuhk.edu.hk
¶ Thermodynamic data for nucleic acids
PALI http://pauling.mbu.iisc.ernet.in/∼pali Phylogeny and alignment of 
homologous protein structures
PASS2 http://caps.ncbs.res.in/campass/ 
pass.html
Structural motifs of protein 
superfamilies
PDB http://www.pdb.org/ Structure data determined by 
X-ray crystallography and NMR
PDB-REPRDB http://mbs.cbrc.jp/pdbreprdb-cgi/ 
reprdb_menu.pl
Representative protein chains, based 
on PDB entries
PDBsum http://www.ebi.ac.uk/thornton-srv/ 
databases/pdbsum/
Summaries and analyses of PDB 
structures
ProTherm http://gibk26.bse.kyutech.ac.jp/jouhou/ 
therm/protherm.html
Thermodynamic data for 
Pro-wild-type and mutant proteins
PSSH http://srs3d.ebi.ac.uk/ Alignments between protein 
sequences and tertiary structures
RNABase http://www.rnabase.org RNA-containing structures from PDB 
and NDB
SCOP http://scop.mrc-lmb.cam.ac.uk/scop Familial and structural protein 
relationships
SCOR http://scor.lbl.gov RNA structural relationships
Sloop http://www-cryst.bioc.cam.ac.uk/∼sloop/ Classiﬁ  cation of protein loops
Structure-Superposition 
Database
http://ssd.rbvi.ucsf.edu Pairwise superposition of TIM-barrel 
structures
SUPERFAMILY http://supfam.org Assignments of proteins to structural 
superfamilies
Retrieval Systems and Database Structure
TESS http://www.cbil.upenn.edu/cgi-bin/
tess/tess
Transcription element search system
Virgil http://www.infobiogen.fr/services/virgil
¶ Database interconnectivity
The cancer research community has not remained 
indifferent to the importance of databases. From the 
big organizations such as National Cancer Institute 
(NCI; http://www.cancer.gov) to smaller research 
groups, scientists have developed databases relat-
ing to the genetics, molecular biology, microarray 103
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Table 2. Cancer related bioinformatics databases.
Database Name URL Description
Atlas of Genetics and 
Cytogenetics in Oncology 
and Haematology
http://www.infobiogen.fr/services/ 
chromcancer/
Cancer-related genes, 
chromosomal abnormalities in 
oncology and haematology, and 
cancer-prone diseases
Cancer Chromosomes http://www.ncbi.nlm.nih.gov/entrez/ 
query.fcgi?db =cancerchromosomes
Cytogenetic, clinical and reference 
information on cancer-related 
aberrations
CGED http://cged.hgc.jp/cgi-bin/input.cgi Cancer gene expression database
COSMIC http://www.sanger.ac.uk/genetics/ 
CGP/cosmic/
Catalogue of somatic mutations in 
cancer: sequence data, samples 
and publications
Germline p53 Mutations http://www.lf2.cuni.cz/win/projects/ 
p53.htm
Mutations in germline_mut_ human 
tumor and cell line p53 gene
IARC TP53 Database http://www.p53.iarc.fr/index.html Human TP53 somatic and germline 
mutations
MTB http://tumor.informatics.jax.org/mtbwi/ 
index.do
Mouse tumor biology database: 
tumor types, genes, classiﬁ  cation, 
incidence, pathology
OncoMine http://www.oncomine.org/ Cancer microarray data by gene or 
cancer type
Oral Cancer Gene Database http://www.tumor-gene.org/Oral/ oral.
html
Cellular and molecular data for 
genes involved in oral cancer
RB1 Gene Mutation DB http://www.verandi.de/joomla/ Mutations in the human 
retinoblastoma (RB1) gene
RTCGD http://rtcgd.ncifcrf.gov/ Mouse retroviral tagged cancer 
gene database
SNP500Cancer http://snp500cancer.nci.nih.gov Re-sequenced SNPs from 102 
reference samples
SV40 Large T-Antigen Mutants http://www.pitt.edu/pipaslab/
¶ Mutations in SV40 large tumor 
antigen gene
Tumor Gene Family Databases http://www.tumor-gene.org/tgdf.html Cellular, molecular and biological 
data about genes involved in 
various cancers
¶ These sites could not be opened at the time of revising the manuscript.
clinical reports and several other aspects of cancer. 
Table 2 lists some of the most prominent data-
bases, which have emerged in respect of cancer 
research. Some of these databases are discussed 
below:
Cancer Chromosomes database
(http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=cancerchromosomes) 
Cancer Chromosomes integrates data from three 
sources: the NCI/NCBI SKY/M-FISH & CGH 
Database, the NCI Mitelman Database of Chromo-
some Aberrations in Cancer, and the NCI Recurrent 
Aberrations in Cancer (Knutsen et al. 2005). This 
is a publicly available database and can be searched 
for cytogenetic, clinical, and/or reference informa-
tion. Similarity reports demonstrating cytogenetic 
and clinical relatedness at varying levels of 
specificity are also returned on querying this 
database.
CGED (Cancer Gene Expression 
Database)
(http://cged.hgc.jp/cgi-bin/input.cgi) 
CGED is a database containing expression proﬁ  les 
and accompanying clinical information of breast, 104
Ahmad et al
Cancer Informatics 2006: 2
colorectal, and hepatocellular cancer related genes 
(Kato et al. 2005). The data in CGED have been 
obtained through collaborative efforts made at the 
Nara Institute of Science and Technology and 
Osaka University School of Medicine to identify 
genes of clinical importance. The expression data 
have been obtained by a high-throughput RT-PCR 
technique (adaptor-tagged competitive PCR). The 
data can be retrieved either using gene identiﬁ  ers 
or by functional categories defined by Gene 
Ontology terms or the SwissProt annotation. Gene 
expression data are displayed in mosaic plots. 
This database also provides for the expression 
patterns of multiple genes, selected by names or 
similarity search of the patterns. The sorting func-
tion enables users for easy recognition of relation-
ships between gene expression and clinical 
parameters.
The Atlas of Genetics and 
Cytogenetics in Oncology and 
Haematology
(http://www.infobiogen.fr/services/chromcancer) 
The Atlas of Genetics and Cytogenetics in Oncol-
ogy and Haematology is a database containing 
information about genes related to cancer (Huret 
et al. 2000). This database contains information in 
the form of cards on cancer related genes, chromo-
somal abnormalities, cancers, and cancer-prone 
diseases. These cards are well-structured papers, 
which represent the body of the Atlas. Cards on 
genes include data on DNA/RNA, protein, muta-
tions, and diseases. Cards on leukemias and solid 
tumours include data on: clinics, cytogenetics, 
genes, hybrid gene and fusion protein. Cards on 
cancer-prone diseases include data on: inheritance 
mode, clinics, neoplastic risk, cytogenetics, genes 
and proteins, mutations. These Cards are linked to 
NCBI published literature database PubMed, and 
to other major databases (nomenclature, cartogra-
phy, gene structure, transcripts, proteins, domain 
families, diseases, mutations, probes). This data-
base has another component called Deep Insights 
and Case Reports. Deep insights are review articles 
related to special topics and the Case Reports sec-
tion is dedicated to rare cytogenetic entities of 
leukemia including the associated prognosis. This 
database also referred to as The Atlas is part of the 
genome project and participates in the research in 
cancer epidemiology.
Database of germline p53 mutations
(http://www.lf2.cuni.cz/proj ects/ germline_mut_ 
p53.htm)
Somatic mutations in the p53 tumor suppressor 
gene are found in many human cancers (Le Roux 
et al. 2005). In addition, germline p53 mutations 
have been identiﬁ  ed in individuals from cancer-
prone families and in isolated cancer patients 
affected at a young age or suffering from multiple 
tumours (Harris 1996; Hollstein et al. 1991). A 
large fraction of the cancer-prone families with 
germline p53 mutation follow the criteria of Li-
Fraumeni syndrome (LFS) (Li et al. 1988;). This 
syndrome is a rare familial autosomal dominant 
cancer syndrome characterised by early-onset 
sarcomas, brain tumours, premenopausal breast 
cancer, leukaemias and adrenocortical tumours. 
It is with this view that a database dedicated to 
p53 mutations has been developed. Genotype-
phenotype correlations, compiled in this data may 
improve the counseling and preventive approaches 
in the affected families. This is a comprehensive 
database of those cases of germline p53 mutations 
for which sufﬁ  cient detail is given in the litera-
ture. In addition to listing all mutations, the 
database includes detailed information about the 
families, affected individuals and their tumours. 
It therefore provides a powerful means for draw-
ing correlations between various aspects of germ-
line p53 mutations. Each p53 mutation (type of 
the mutation, exon and codon affected by the 
mutation, nucleotide and amino acid change), 
have been explained. In addition, it has the infor-
mation on the family history of cancer, diagnosis 
of LFS, each affected individual (sex, generation, 
p53 status, from which parent the mutation was 
inherited) and each tumour (type, age of onset, 
p53 status (loss of heterozygosity and immunos-
taining). Each entry contains the original research 
article as reference(s).
COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) 
COSMIC is a database designed to store and 
display somatic mutation information-relevant for 
cancer (Forbes et al. 2006). In particular, it con-
tains information relating to human cancers. 
COSMIC contains information on publications, 
samples and mutations implicated in cancer. It 
also includes samples, which have been found to 
be negative for mutations during screening. 105
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This allows the calculation of frequency data 
normalized by control frequencies for mutations 
in different genes in different cancer types. 
Samples entered include benign neoplasms and 
other benign proliferations, in situ and invasive 
tumors, recurrences, metastases and cancer cell 
lines. Histology and tissue ontology has also been 
created in this database. All mutations are mapped 
to a single version of each gene. The data can be 
queried by tissue, histology or gene and dis-
played as a graph, as a table or exported to other 
formats.
EHCO database
(http://ehco. nchc. org. tw) EHCO (Encyclopedia 
of Hepatocellular Carcinoma genes Online) is an 
integrative database for HCC (hepatocellular car-
cinoma) research. It carries gene annotations col-
lected by computer-assisted mining, manual 
curation, and extraction from public databases. 
Currently EHCO contains information for about 
3500 HCC-related genes. Various entries in this 
database can be compared online. Detailed annota-
tions for particular genes, including sequence, 
ontology, cited literature, and expression proﬁ  les 
are also available.
Human p53 database
(http://metalab.unc.edu/dnam/mainpage.html) 
A collection of databases relating to p53 gene 
mutations, lacI and lacZ is available on this web-
site (Cariello et al. 1994; Cariello et al. 1996). 
There are nearly 6000 entries corresponding to 
p53, 200 for lacZ and 1500 of lacI. In addition 
1500 transgenic and 8000 bacterial entries are also 
included. A software for analysis of the databases 
is also included. Each database has a separate 
software analysis program. All these databases 
include information about mutations such as base 
position, the nature of the mutation, amino acid 
position, molecular weight and the name of mutant 
amino acid, the local sequence around a mutation 
and literature citation as the source of listed 
information. Information speciﬁ  c to the p53 data-
base includes cancer type, cell origin, loss of 
heterozygosity.
IARC TP53 Database
(http://www.p53.iarc.fr/index.html) 
The IARC TP53 Database compiles data on human 
somatic and germline TP53 genetic variations that 
are reported in the published literature. (Olivier 
et al. 2002; Hernandez-Boussard 1999; Hainaut 
et al. 1997; Hainaut et al. 1998 ; Hollstein et al. 
1994, Hollstein et al. 1996). With over 18,500 
somatic and 225 germline mutations and 1,000 
citations in the world literature, this database is 
now recognized as a major source of information 
on TP53 mutation patterns in human cancer. It can 
be searched and analyzed online and is useful to 
draw hypotheses on the nature of the molecular 
events involved in TP53 mutagenesis and on the 
natural history of cancer.
ITTACA Gene expression and 
clinical database
(http://bioinfo-out.curie.fr/ittaca/)
ITTACA is a database of microarray experimental 
results and clinical information retrieved form 
published papers (Elﬁ  lali et al. 2006). It contains 
information on breast carcinoma, bladder carci-
noma, and uveal melanoma. Online service also 
allows some basic statistical analysis of the data-
base such as the comparison of expression distribu-
tion proﬁ  les, tests for differential expression, and 
patient survival analyses.
The Mouse Tumor Biology 
Database (MTB)
(http ://www.informatics.j ax. org)
MTB database compiles and shares information 
about tumor frequency, genetics, and pathology in 
genetically denned mice (i.e., transgenics, targeted 
mutations, and inbred strains) (Bult et al. 2001). 
The database collects crucial information about 
incidence of different types of tumors in different 
strains, mutations relating to speciﬁ  c genes and 
tumors corresponding to them, which have been 
reported in medical journals. Existing standards 
for anatomy, tumor names, gene names, and strain 
names are well enforced, enabling direct links to 
information across MTB entries and to other rel-
evant databases.
The Tumor Gene Family 
Databases (TGDBs)
(http://condor.bcm.tmc.edu/ermb/tgdb/tgdf. html) 
TGDB is made up of two databases viz. Oral 
Cancer Gene Database (OrCGDB) and Breast 
Cancer Gene Database (BCGD). Both these 106
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databases contain information on a mechanism of 
oncogenic activation, regulation, frequency of 
involvement in various tumor types, and chromo-
somal location for the genes involved in cancer 
(e.g. proto-oncogenes and tumor supressor genes). 
Data about the encoded proteins includes the cell 
type in which they are found, subcellular location, 
DNA, protein, and ligand binding, role in develop-
ment, and normal biochemical function.
QSAR and in-silico analysis of 
molecular recognition
Once the molecular mechanism and the chemistry of 
a disease is understood, the next crucial task is to ﬁ  nd 
a suitable cure for it. Atypical requirement is to ﬁ  nd 
a suitable drug target and the drug itself (Brooijmans 
and Kuntz 2003). Target discovery draws much on 
bioinformatics tools today and in case of cancer the 
DNA and protein molecules both can be potential 
targets for drugs (Choudhary et  al. 2005; 
Bandyopadhyaya et al. 2005; Bhongade et al. 2004; 
Asseffa et al. 2003; Gellert et al. 2005; Khaleque 
et al. 2006; Yao et al. 2005; McColl et al. 2005).
Drug discovery is a complex, expensive and 
very time-consuming exercise, as there is no single 
systematic way to automatically discover a drug 
even when the disease and targets have been well 
understood (Dixit and Mitra 2002).
There may be millions of candidate molecules 
if in-silico ﬁ  ltering is not performed. Experiments 
cannot be performed on such large number of drug 
candidates due to prohibitive costs both in terms 
of time and money. Quantitative structure-activity 
relationship (QSAR) studies form the center stage 
when a protein (typically an enzyme) is the target 
and there is a need to ﬁ  nd a suitable molecule, 
which can control (inhibit) the activity of its target. 
The basic principle of such a study is the structure-
dependence of chemical activity. QSAR has existed 
much longer than the ﬁ  rst popularity of computers, 
because chemical structure has always been able 
to explain at least some aspects of chemical prop-
erties. However, with the availability of powerful 
computers and high quality databases of molecular 
libraries and interactions have made QSAR an 
essential component of drug discovery today. Role 
of structure in determining the activity of a chem-
ical compound is illustrated in an example of 
protein-ligand complex in Fig 1.
QSAR based (in-silico) analysis may be better 
regarded as an exercise to screen or ﬁ  lter drug 
candidates, before they are subjected to more inten-
sive calculations such as docking or an experimen-
tal measurement of activity (in-vitro) and ﬁ  nally 
under real conditions (in-vivo). Many times this 
step will pick up a dozen of drug candidate from a 
library of millions of well-studied molecules. Tra-
ditional QSAR is speciﬁ  c to a particular target or 
enzyme and all the screening is performed on drug 
candidates (ligand molecules). These ligand mol-
ecules are very diverse and in order to screen them 
suitably, we need to describe their structure as well 
as chemical nature. This leads to the issue of ﬁ  nding 
descriptors of molecular properties of ligands and 
drugs. Hundreds of molecular properties or 
Figure 1. Identical A & B Chain Residues of 1A1E in complex with its ligand (ACE-PTR-GLU-DIY). Ligand in red.107
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descriptors are used to represent molecules (Labute 
2000; Xue and Bajorath 2000; Wildman and Crip-
pen 2002; Gozalbes et al. 2002).
These properties may be purely geometric, topo-
logical, electromagnetic, classical and quantum-
mechanical. Often, predicting activity of a 
protein-ligand combination if the descriptors of the 
ligand are known carries out this screening. Regres-
sion techniques such as Principal Component 
Analysis (PCA), Neural Network and Multi-variate 
correlation are the major techniques used for this 
purpose. In the following we review some of these 
techniques and special reference will be wherever a 
successful application to cancer has been reported.
A large number of molecular descriptors are 
available and used (Todeschini and Consonni; 
Labute 2000; Wildman and Crippen 2002; Hansch 
et al. 1995; Basak et al. 1980; Gozalbes et al. 2002; 
Pirard and Picket 2000; Basak et al. 1981; Basak 
et al. 1982; Kier and Hall 1999; Raevsky 1999; Xue 
and Bajorath 2000). Molecular descriptors used in 
QSAR for a unique representation and identiﬁ  cation 
of ligand molecules, which are likely to be drug 
candidates, may be classiﬁ  ed as follows:
Constitutional descriptors such as molecular 
weight, van der Waals volume, electronegativities, 
polarizability, number of atoms, non-H atoms, 
number of H bonds, multiple bonds, bond orders, 
aromatic ratio, number of rings, number of double 
and triple bonds, aromatic bonds, 3 different types 
of (n-membered) rings, benzene-like rings.
Topological descriptors such as total structure 
connectivity index, Pogliani index, ramiﬁ  cation 
index, polarity number, average vertex distance 
degree, mean square distance index (Balaban), 
Schultz Molecular Topological Index (MTI), 
square reciprocal distance sum index, quasi-Wiener 
index (Kirchhoff number), spanning tree number, 
hyper-distance-path index, reciprocal hyper-
distance-path index, detour index, hyper-detour 
index, reciprocal hyper-detour index, distance/
detour index, all-path Wiener index, Wiener-type 
index from Z weighted distance matrix (Barysz 
matrix), molecular electrotopological variation, 
E-state topological parameter, Kier symmetry 
index eccentricity, mean distance degree deviation, 
unipolarity, centralization, variation.
Walk and path counts such as molecular walk 
counts, total walk count, self-returning walk counts, 
molecular path counts, molecular multiple path 
counts, total path count, conventional bond-order ID 
number, Randic ID number, Balaban ID number, 
ratio of multiple path count over path count, difference 
between multiple path count and path count.
Connectivity indices such as connectivity 
indices, average connectivity indices, valence con-
nectivity indices, average valence connectivity 
indices, solvation connectivity indices, modiﬁ  ed, 
reciprocal distance Randic-type index, reciprocal 
distance squared Randic-type index.
Information indices such as information index 
on molecular size, total information index of 
atomic composition, mean information index on 
atomic composition, mean information content 
on the distance equality, mean information con-
tent on the distance magnitude, mean information 
content on the distance degree equality, mean 
information content on the distance degree mag-
nitude, total information content on the distance 
equality, total information content on the distance 
magnitude, mean information content on the vertex 
degree equality, mean information content on the 
vertex degree magnitude, graph vertex complexity 
index, graph distance complexity index (log), 
Balaban U index, Balaban V index, Balaban X 
index, Balaban Y index Basak indices of neighbor-
hood symmetry.
2D autocorrelations Broto-Moreau autocor-
relations of a topological structure, Moran autocor-
relations, Geary autocorrelations.
Edge adjacency indices edge connectivity 
index of order 0, edge connectivity index of order 
1 eigenvalues from edge adj. matrix weighted by 
edge degrees, eigenvalues from edge adj. matrix 
weighted by dipole moments, eigenvalues from 
edge adj. matrix weighted by resonance integrals 
spectral moments from edge adj. matrix, spectral 
moments from edge adj. matrix weighted by edge 
degrees, spectral moments from edge adj. matrix 
weighted by dipole moments, spectral moments 
from edge adj. matrix weighted by resonance 
integrals.
Eigenvalue-based indices   Lovasz-Pelikan index 
(leading eigenvalue), leading eigenvalue from Z 
weighted distance matrix (Barysz matrix), leading 
eigenvalue from mass weighted distance matrix, 
leading eigenvalue from van der Waals weighted 
distance matrix, leading eigenvalue from electro-
negativity weighted distance matrix, leading eigen-
value from polarizability weighted distance matrix.
Geometrical descriptors 3D-Wiener index, 
3D-Balaban index, 3D-Harary index average 
geometric distance degree, D/D index, average 
distance/distance degree gravitational index G1, 108
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gravitational index G2 (bond-restricted), radius of 
gyration (mass weighted), span R, average span R.
Functional group counts terminal primary 
C(sp3), total secondary C(sp3), total tertiary C(sp3), 
total quaternary C(sp3), ring secondary C(sp3), ring 
tertiary C(sp3), ring quaternary C(sp3) aromatic 
C(sp2), unsubstituted benzene C(sp2), substituted 
benzene C(sp2), non-aromatic conjugated C(sp2), 
terminal primary C(sp2), aliphatic secondary 
C(sp2), aliphatic tertiary C(sp2), allenes groups, 
terminal C(sp), non-terminal C(sp) cyanates 
(aliphatic), cyanates (aromatic), isocyanates (alip-
hatic), isocyanates (aromatic), thiocyanates 
(aliphatic), thiocyanates (aromatic), isothiocy-
anates (aliphatic), isothiocyanates (aromatic).
Charge descriptors maximum positive charge, 
maximum negative charge, total positive charge, 
total negative charge, total absolute charge (elec-
tronic charge index – ECI), mean absolute charge 
(charge polarization), total squared charge, relative 
positive charge, relative negative charge, submo-
lecular polarity parameter, topological electronic 
descriptor, topological electronic descriptor (bond 
resctricted), partial charge weighted topological 
electronic descriptor, local dipole index.
Molecular properties unsaturation index hy-
drophilic factor Ghose-Crippen molar refractivity 
topological polar and non-polar surface area.
Many more descriptors may be calculated and 
comprehensive lists can be found. A comprehen-
sive review of molecular descriptors is presented 
by Karelson (2000). Many free and commercial 
software also provide a current list of descriptors 
(e.g. http://www.talete.mi.it/products/dragon_mo-
lecular_descriptors.htm and http://preadmet.bm-
drc.org/preadmet/query/query1.php, from where, 
list of many of the above descriptors is compiled.). 
An excellent coverage of issues and topics related 
to QSAR is also provided in a text book by 
Gasteiger and Engel (2003).
After the descriptors of molecules have been 
calculated, redundant descriptors are removed 
using Principal Component Analysis or Multi-
variate analysis (Jolliffe 1986: Xue and Bajorath 
2000). Many commercial and some free software 
programs are now available which may be used 
to calculate some of the descriptors and/or 
develop a QSAR model using them. Some of 
these programs are listed in Table 3. These soft-
wares can give few key descriptors (such as 
5 descriptors in Molinspiration) or a very large 
number of them (e.g. DRAGON gives more than 
1500 descriptors), which will need to be reduced 
by some analysis. 
Cancer researchers have frequently used these 
methods for a systematic ﬁ  ltering of potential drug 
candidates or for generalizing principles governing 
the choice of ligands that prefer to bind to a particu-
lar family of proteins in a selective and competitive 
way. Several aspects of cancer have been studied 
using QSAR techniques. Classical efforts at using 
QSAR for cancer drug research date back to 1970s 
(e.g. Hansch 1979). Antitumour drugs have remained 
a regular subject of investigation using QSAR (Ren 
and Lien 2004). During that time, focus was to dis-
cover drugs for chemotherapy. As cases of multidrug 
resistance were observed, a need to have alternative 
medicine for the same action were felt. Thus, a large 
number of researchers have focused on multidrug 
resistance in regards to chemotherapy and employed 
QSAR as a means to solve this problem. For exam-
ple Breier et al. (2000) have studied multidrug 
resistance (MDR) for L1210/VCR-1 and L1210/
VCR-2 cell lines in regards to leukemia treatment. 
They related the developed adaptation and drug 
resistance to structure descriptors of drugs viz. bind-
ing energy, molecular weight, pKa, log P etc. Klop-
man et al. (1997) have studied 609 diverse compounds 
to understand the drug resistance in P388/ADR 
resistant cell lines. In this study they identiﬁ  ed sev-
eral structural characteristics of MDR such as log P 
and graph index. More advanced techniques of 
QSAR such as Comparative Molecular Simillarity 
Index Analysis (CoMSIA) have been used to study 
antiviral and anticancer drugs targeting Thymidine 
Kinase (e.g. Bandyopadhyaya et al. 2005, Bhon-
gade and Gadad 2004). Principle of CoMSIA is the 
alignment and comparison of drug molecules by 
comparing their similarity indices (selected descrip-
tors). A similar approach, called Comparative 
Molecular Field Analysis (CoMFA) focuses on 
molecular ﬁ  eld descriptors for this purpose (Cramer 
et al. 1988). Epidermal Growth Factor Receptors 
(EGFR) are one of the most popular class of proteins 
studied by QSAR method. Assefa et al. (2003) have 
used CoMFA for such a study and concluded that 
electrostatics and hydrophobicity descriptors play 
the most important role in EPGR target binding. 
Similarly, electrotopological state atom (ETSA) 
indices have been shown to play the most important 
role in anti tumour effect of pyridoacridine ascidi-
demin analagues (Debnath et al. 2003). Thus, if a 
drug is available for chemotherapy and more such 
drugs are required to have redundancy against drug 109
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resistance, previously known successful drug/ 
inhibitor is compared with a large data set of diverse 
molecules and those having their molecular indices 
(CoMSIA), or molecular ﬁ  elds (CoMFA) similar to 
that drug are picked up for potential use. Most recent 
QSAR related cancer studies have focused on 
genomic aspects of cancer related drug discovery 
(Workman 2001, Jung et al. 2003). This allows for 
individual prescriptions based on the genetic makeup 
of the patient. Thus, the possibility of having a large 
number of drugs having similar inhibitory ability 
but diverse genetic response opens a myriad of pos-
sibilities for cancer related research for peoples and 
individuals.
Summary
A number of databases directly and indirectly 
useful for cancer research have been reviewed. 
QSAR techniques and its application to cancer 
research have been outlined.
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